Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3

Authors

Gunjal Garg, Washington University School of Medicine in St. LouisFollow
Jesse Gibbs, Washington University School of Medicine in St. LouisFollow
Brian Belt, Washington University School of Medicine in St. Louis
Matthew A. Powell, Washington University School of Medicine in St. Louis
David G. Mutch, Washington University School of Medicine in St. Louis
Peter Goedegebuure, Washington University School of Medicine in St. LouisFollow
Lynne Collins, Washington University School of Medicine in St. LouisFollow
David Piwnica-Worms, Washington University School of Medicine in St. Louis
William G. Hawkins, Washington University School of Medicine in St. LouisFollow
Dirk Spitzer, Washington University School of Medicine in St. Louis

Journal

BMC Cancer

Publication Date

2014

Volume

14

Inclusive Pages

35

Document Type

Open Access Publication

DOI

10.1186/1471-2407-14-35

Rights and Permissions

Garg et al.: Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer 2014 14:35. doi:10.1186/1471-2407-14-35

Recommended Citation

Garg, Gunjal; Gibbs, Jesse; Belt, Brian; Powell, Matthew A.; Mutch, David G.; Goedegebuure, Peter; Collins, Lynne; Piwnica-Worms, David; Hawkins, William G.; and Spitzer, Dirk, "Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3." BMC Cancer. 14, 35. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2164